2023
The effect of duration of untreated psychosis (DUP) on the risk for hospitalization after admission to a first episode service
Ferrara M, Guloksuz S, Hazan H, Li F, Tek C, Sykes L, Riley S, Keshavan M, Srihari V. The effect of duration of untreated psychosis (DUP) on the risk for hospitalization after admission to a first episode service. Schizophrenia Research 2023, 260: 198-204. PMID: 37688984, DOI: 10.1016/j.schres.2023.08.005.Peer-Reviewed Original ResearchConceptsFirst-episode psychosis servicesLength of stayUntreated psychosisPsychiatric hospitalizationFirst-episode servicesDuration of hospitalizationIncidence rate ratiosNon-affective psychosisNew Haven areaPoisson regression modelsPatient characteristicsHospitalization ratesRecent onsetMedical recordsHospitalizationEffect of durationNegative binomial regressionSpecialized treatmentPsychosisRate ratioBinomial regressionAdmissionDUPEnrollmentFirst year
2022
Granular analysis of pathways to care and durations of untreated psychosis: A marginal delay model
Mathis W, Ferrara M, Burke S, Hyun E, Li F, Zhou B, Cahill J, Kline E, Keshavan M, Srihari V. Granular analysis of pathways to care and durations of untreated psychosis: A marginal delay model. PLOS ONE 2022, 17: e0270234. PMID: 36472968, PMCID: PMC9725156, DOI: 10.1371/journal.pone.0270234.Peer-Reviewed Original ResearchUntreated psychosisAntipsychotic prescriptionsEarly detection campaignsPatient characteristics influencesEarly detection effortsPatient characteristicsClinical nodesLonger DUPFunctional declineOutpatient programPsychosis onsetSpecialized treatmentPsychosisNumber of daysDetection campaignsNetworks of careHigh functioningPrescriptionEnrollmentPTCDurationStart date
2020
Adoption of Immune Checkpoint Inhibitors and Patterns of Care at the End of Life.
Riaz F, Gan G, Li F, Davidoff AJ, Adelson KB, Presley CJ, Adamson BJ, Shaw P, Parikh RB, Mamtani R, Gross CP. Adoption of Immune Checkpoint Inhibitors and Patterns of Care at the End of Life. JCO Oncology Practice 2020, 16: e1355-e1370. PMID: 32678688, PMCID: PMC8189605, DOI: 10.1200/op.20.00010.Peer-Reviewed Original ResearchConceptsImmune checkpoint inhibitorsEnd of lifeUse of chemotherapySystemic cancer therapySystemic therapyCheckpoint inhibitorsColon cancerElectronic health record-derived databaseUse of ICIsFDA approvalCell lung cancerPatterns of careCare of patientsMicrosatellite stable colon cancerMSS colon cancerPearson's chi-square testDrug Administration approvalPatient-level dataCancer therapyDays of lifeChi-square testAggressive therapyBiologic therapyPatient characteristicsTreatment patternsThe adoption of immune checkpoint inhibitors and patterns of care at the end of life.
Riaz F, Gan G, Li F, Davidoff A, Adelson K, Presley C, Adamson B, Shaw P, Parikh R, Mamtani R, Gross C. The adoption of immune checkpoint inhibitors and patterns of care at the end of life. Journal Of Clinical Oncology 2020, 38: 12027-12027. DOI: 10.1200/jco.2020.38.15_suppl.12027.Peer-Reviewed Original ResearchNon-small cell lung cancerImmune checkpoint inhibitorsUse of chemotherapyMSS colon cancerEnd of lifeSystemic therapySystemic cancer therapyColon cancerFDA approvalCheckpoint inhibitorsBiologic therapyPatient characteristicsUse of ICIsCell lung cancerPatterns of careCare of patientsMicrosatellite stable colon cancerPearson's chi-square testPatient-level dataCancer therapyDays of lifeDe-identified databaseSignificant increaseChi-square testAggressive therapy
2019
Association between pre-diagnosis BMI, physical activity, pathologic complete response, and chemotherapy completion in women treated with neoadjuvant chemotherapy for breast cancer
Usiskin I, Li F, Irwin ML, Cartmel B, Sanft T. Association between pre-diagnosis BMI, physical activity, pathologic complete response, and chemotherapy completion in women treated with neoadjuvant chemotherapy for breast cancer. Breast Cancer 2019, 26: 719-728. PMID: 31119682, DOI: 10.1007/s12282-019-00974-3.Peer-Reviewed Original ResearchConceptsPathologic complete responseChemotherapy completionComplete responseNeoadjuvant chemotherapyLower BMIResidual diseaseBreast cancerPhysical activityNeoadjuvant breast cancer treatmentRetrospective case-control studyUnconditional logistic regression modelsCompletion of chemotherapyMedical record reviewBreast cancer survivalLower mean BMICase-control studyPhysical activity 1Breast cancer treatmentLogistic regression modelsBreast cancer diagnosisMean BMIPatient characteristicsRecord reviewPurposePhysical activityCancer survival